Radiopharm Theranostics received a positive recommendation from the Data Safety and Monitoring Committee to advance to Cohort 4 in the Phase 1 HEAT clinical trial for 177Lu-RAD202. This trial is part of their innovative pipeline targeting various solid tumor cancers, including lung, breast, and prostate cancers.

A multicenter study analyzed the effectiveness of stereotactic radiotherapy for rib metastases from prostate cancer, focusing on local control, pain response, and treatment tolerance. The findings contribute to understanding treatment options for patients with metastatic prostate cancer.

A study identifies subclonal complete loss of CDKN1B as a prevalent genomic alteration in prostate cancer, highlighting its associations with race and patient outcomes. This discovery may inform future research and treatment strategies in prostate cancer management.

A case report highlights penile metastasis from castration-resistant prostate cancer, providing insights into this rare occurrence. This study contributes to the understanding of metastatic patterns in advanced prostate cancer.

Pfizer presented several late-breaking data at ASCO, highlighting advancements in lung, colorectal, and prostate cancer. However, the most significant results are anticipated later this year.